ABX-196

DB16339InvestigationalSmall molecule

ABX-196 is under investigation in clinical trial NCT03897543 (ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma).

Mechanism: Pharmacologically active on Antigen-presenting glycoprotein CD1d
Curator reviewed
Formula / weight: C₅₀H₉₈N₂O₉ · 871.339 g/mol (avg)
Code names: ABX-196 · PBS 96

Resolves to

Compound

UNIISOI87F7GN2CAS1161877-58-2

Structure

InChIKeyVITDDUXZOHEQMU-BYSUZVQFSA-NSMILESCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@H]1O[C@H](CNC(C)=O)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@H](O)CCCCCCCCCCCCCC

Targets

P15813CD1D

What you can answer from here — as of September 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with ABX-196, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account